BACKGROUND: The current study was conducted to determine the frequency and association between recurrence-free survival (RFS) and MET and catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevations in patients with early stage breast cancer. METHODS: Tumor DNA was extracted from 971 formalin-fixed, paraffin-embedded early breast cancers for molecular inversion probes arrays. Data were segmented using the single-nucleotide polymorphism (SNP)-FASST2 segmentation algorithm. Copy number gains were called when the copy number of each segment was greater than 2.3 or 1.7, respectively. RFS was estimated by the Kaplan-Meier method. Cox proportional hazards models were fit to determine independent associations between copy number and RFS. RESULTS: Of the 971 tumors studied, 82 (8.44%) and 134 (13.8%) had an elevation of the MET or PIK3CA copy number, respectively, and 25.6% of tumors with a MET copy number elevation had a PIK3CA copy number elevation. Patients with either a MET or PI3KCA high copy number tended to have poorer prognostic features (larger tumor size, higher tumor grade, and hormone receptor negativity). Both MET and PIK3CA high copy numbers were more likely to occur in patients with triple receptor-negative disease (P = .019 and P < .001, respectively). At a median follow-up of 7.4 years, there were 252 cases of disease recurrence. The 5-year RFS rates were 63.5% and 83.1% for MET high copy number and MET normal/low copy number, respectively (P = .06) and 73.1%, and 82.3% for PIK3CA high copy number and PIK3CA normal/low copy number, respectively (P = .15). A high copy number for either gene was not found to be an independent predictor of RFS. CONCLUSIONS: A high copy number of MET or PIK3CA was found to be associated with poorer prognostic features and triple receptor-negative disease. Coamplification was frequent. Patients with tumors with high MET copy numbers tended to have a worse RFS.
BACKGROUND: The current study was conducted to determine the frequency and association between recurrence-free survival (RFS) and MET and catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevations in patients with early stage breast cancer. METHODS:Tumor DNA was extracted from 971 formalin-fixed, paraffin-embedded early breast cancers for molecular inversion probes arrays. Data were segmented using the single-nucleotide polymorphism (SNP)-FASST2 segmentation algorithm. Copy number gains were called when the copy number of each segment was greater than 2.3 or 1.7, respectively. RFS was estimated by the Kaplan-Meier method. Cox proportional hazards models were fit to determine independent associations between copy number and RFS. RESULTS: Of the 971 tumors studied, 82 (8.44%) and 134 (13.8%) had an elevation of the MET or PIK3CA copy number, respectively, and 25.6% of tumors with a MET copy number elevation had a PIK3CA copy number elevation. Patients with either a MET or PI3KCA high copy number tended to have poorer prognostic features (larger tumor size, higher tumor grade, and hormone receptor negativity). Both MET and PIK3CA high copy numbers were more likely to occur in patients with triple receptor-negative disease (P = .019 and P < .001, respectively). At a median follow-up of 7.4 years, there were 252 cases of disease recurrence. The 5-year RFS rates were 63.5% and 83.1% for MET high copy number and MET normal/low copy number, respectively (P = .06) and 73.1%, and 82.3% for PIK3CA high copy number and PIK3CA normal/low copy number, respectively (P = .15). A high copy number for either gene was not found to be an independent predictor of RFS. CONCLUSIONS: A high copy number of MET or PIK3CA was found to be associated with poorer prognostic features and triple receptor-negative disease. Coamplification was frequent. Patients with tumors with high MET copy numbers tended to have a worse RFS.
Authors: Priscilla F McAuliffe; Funda Meric-Bernstam; Gordon B Mills; Ana M Gonzalez-Angulo Journal: Clin Breast Cancer Date: 2010-11 Impact factor: 3.225
Authors: Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: Shuying Liu; Shunqiang Li; Bailiang Wang; Wenbin Liu; Mihai Gagea; Huiqin Chen; Joohyuk Sohn; Napa Parinyanitikul; Tina Primeau; Kim-Anh Do; George F Vande Woude; John Mendelsohn; Naoto T Ueno; Gordon B Mills; Debu Tripathy; Ana M Gonzalez-Angulo Journal: Mol Cancer Ther Date: 2018-12-05 Impact factor: 6.261
Authors: Jiqing Sai; Philip Owens; Sergey V Novitskiy; Oriana E Hawkins; Anna E Vilgelm; Jinming Yang; Tammy Sobolik; Nicole Lavender; Andrew C Johnson; Colt McClain; Gregory D Ayers; Mark C Kelley; Melinda Sanders; Ingrid A Mayer; Harold L Moses; Mark Boothby; Ann Richmond Journal: Clin Cancer Res Date: 2016-12-21 Impact factor: 12.531
Authors: Vandana G Abramson; M Cooper Lloyd; Tarah Ballinger; Melinda E Sanders; Liping Du; Darson Lai; Zengliu Su; Ingrid Mayer; Mia Levy; Delecia R LaFrance; Cindy L Vnencak-Jones; Yu Shyr; Kimberly B Dahlman; William Pao; Carlos L Arteaga Journal: Breast Cancer Res Treat Date: 2014-04-11 Impact factor: 4.872
Authors: R Nadal; M Salido; L Nonell; M Rodríguez-Rivera; E Puigdecanet; J L Garcia-Puche; M Macià; J M Corominas; M J Serrano; J A Lorente; F Solé Journal: Tumour Biol Date: 2014-10-07
Authors: Sara M Tolaney; David R Ziehr; Hao Guo; Mei R Ng; William T Barry; Michaela J Higgins; Steven J Isakoff; Jane E Brock; Elena V Ivanova; Cloud P Paweletz; Michelle K Demeo; Nikhil H Ramaiya; Beth A Overmoyer; Rakesh K Jain; Eric P Winer; Dan G Duda Journal: Oncologist Date: 2016-10-27 Impact factor: 5.837
Authors: F Zagouri; Z Bago-Horvath; F Rössler; A Brandstetter; R Bartsch; C A Papadimitriou; C Dimitrakakis; A Tsigginou; I Papaspyrou; A Giannos; M-A Dimopoulos; M Filipits Journal: Br J Cancer Date: 2013-02-19 Impact factor: 7.640